Novo London, Tandem, Zealand, NewAmsterdam, Esperion, Viatris, and Dario Q3 ’24 Earnings; Altimmune Ph3 Obesity Program
Here is a brief preview of this blast: A series of cardiometabolic-related news items have been observed from Novo Nordisk, Tandem Diabetes Care, Zealand Pharma, Altimmune, NewAmsterdam Pharma, Esperion, Viatris, and DarioHealth. Below, FENIX provides highlights and insights for the respective news items.